SharePoint
Hepatitis Rearch Center Logo
:::
:::
肝炎研究中心 > 中心簡介 > 研究成果

2018年論文發表

  1. Block TM, Alter H, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten TF, Guo JT, Hoshida Y, Kowdley KV, Li W, Lok AS, McMahon B, Mehta A, Perrillo R, Rice CM, Rinaudo J, Schinazi RF, Shetty K. Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop. Antiviral Res. 2018 Feb;150:93-100.
  2. Chang KV, Chen JD, Wu WT, Huang KC, Hsu CT, Han DS. Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Liver Cancer. 2018 Mar;7(1):90-103. doi: 10.1159/000484950. Epub 2017 Dec 9. Review.
  3. Chang KV, Wu WT, Huang KC, Jan WH, Han DS. Limb muscle quality and quantity in elderly adults with dynapenia but not sarcopenia: An ultrasound imaging study. Exp Gerontol. 2018 Jul 15;108:54-61. doi: 10.1016/j.exger.2018.03.019. Epub 2018 Mar 28.
  4. Chen ST, Ni YH, Li CC, Liu SH. Hepcidin correlates with interleukin-1beta and interleukin-6 but not iron deficiency in children with Helicobacter pylori infection. Pediatr Neonatol. 2018 Feb 9. pii: S1875-9572(17)30333-9..
  5. Chen ST, Ni YH, Liu SH. Potential association of IL1B polymorphism with iron deficiency risk in childhood Helicobacter pylori infection. J Pediatr Gastroenterol Nutri 2018; 66(2):e36-e40.
  6. Cheng SY, Li MC, Chia SL, Huang KC, Chiu TY, Chan DC, Chiu HM. Factors Affecting Compliance With Confirmatory Colonoscopy After a Positive Fecal Immunochemical Test in a National Colorectal Screening Program. Cancer. 2018 Mar 1;124(5):907-915. doi: 10.1002/cncr.31145. Epub 2017 Nov 22.
  7. Chien CS, Chen YH, Chen HL, Wang CP, Wu SH, Ho SL, Huang WC, Yu CH, Chang MH. Cells responsible for liver mass regeneration in rats with 2-acetylaminofluorene/partial hepatectomy injury. J Biomed Sci. 2018; 25(1):39. doi: 10.1186/s12929-018-0441-5.
  8. Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2018 Dec 5. [Epub ahead of print]
  9. Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, Ni YH, Liu CJ, Lin YC, Lesmana LA, Kim SU, Hashimoto E, Hamaguchi M, Goh KL, Fan J, Duseja A, Dan YY, Chawla Y, Farrell G, Chan HL. The Asia-Pacific Working Party on nonalcoholic fatty liver disease guidelines 2017 Part 2: Management and special groups. J Gastroenterol Hepatol. 2018 Jan;33(1):86-98.
  10. Chua HH, Chou HC, Tung YL, Chiang BL, Liao CC, Liu HH, Ni YH. Intestinal dysbiosis featuring abundance of Ruminococcus gnavus associates with allergic diseases in infants. Gastroenterology. 2018 Jan;154(1):154-167.
  11. Ho CM, Lee CH, Lee MC, Zhang JF, Wang JY, Hu RH, Lee PH. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: A nationwide high-risk cohort study. BMC Cancer 2018;18:401
  12. Ho CM, Wakabayashi G, Yeh CC, Hu RH, Sakaguchi T, Hasegawa Y, Takahara T, Nitta H, Sasaki A, Lee PH. Comprehensive evaluation of liver resection procedures: Surgical mind development through cognitive task analysis. Journal of Visualized Surgery 2018;4:21
  13. Hong CM, Liu CH, Su TH, Yang HC, Chen PJ, Chen YW, Kao JH, Liu CJ. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. J Microbiol Immunol Infect. 2018 Sep 26. pii: S1684-1182(18)30403-1
  14. Hsieh MH, Yeh ML, Su TH, Liu TW, Huang CF, Huang CI, Wang SC, Huang JF, Dai CY, Kao JH, Chuang WL, Chen PJ, Liu CJ, Yu ML. Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. J Formos Med Assoc. 2018 Jun;117(6):497-504.
  15. Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, Chu HC, Huang YH, Chien RN, Liaw YF. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc. 2018 Jul;117(7):588-597.
  16. Hsu SH, Huang HL, Lu CW, Cheng SY, Lee LT, Chiu TY, Huang KC. Tour leaders with detailed knowledge of travel-related diseases play a key role in disease prevention. Medicine (Baltimore). 2018 Feb;97(6):e9806. doi: 10.1097/MD.0000000000009806.
  17. Hu HH, Liu J, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY, Quan Y, Xia NS, Chen CJ, Chen PJ, Yang HI. Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients. Clin Gastroenterol Hepatol. 2018 May 9. pii: S1542-3565(18)30472-5. [Epub ahead of print]
  18. Hu KC, Wu MS, Chu CH, Wang HY, Lin SC, Liu CC, Su TH, Liao WC, Chen CL, Liu CJ, Shih SC. Decreased Colorectal Adenoma Risk after Helicobacter pylori Eradication: A Retrospective Cohort Study. Clin Infect Dis. 2018 Dec 19. doi: 10.1093/cid/ciy591. [Epub ahead of print]
  19. Hu MH, Huang TT, Chao TI, Chen LJ, Chen YL, Tsai MH, Liu CY, Kao JH, Chen KF. Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma. Liver Int. 2018 May 24. doi: 10.1111/liv.13887.
  20. Huang KW, Yang PC, Pua U, Kim MD, Li SP, Qiu YD, Song TQ, Liang PC. The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma. J Surg Oncol. 2018 Jun 7. doi: 10.1002/jso.25110. [Epub ahead of print]
  21. Huang SF, Chang IC, Hong CC, Yen TC, Chen CL, Wu CC, Tsai CC, Ho MC, Lee WC, Yu HC, Shen YY, Eng HL, Wang J, Tseng HH, Jeng YM, Yeh CT, Chen CL, Chen PJ, Liaw YF. Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B. Hepatol Commun. 2018 Apr 18;2(6):747-759. eCollection 2018 Jun.
  22. Hung CM, Liu CH, Su TH, Yang HC, Chen PJ, Chen YW, Kao JH, Liu CJ. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: real-world data. J Microbiol Immunol Infect 2018 Sep 26. pii: S1684-1182(18)30403-1. (co-corresponding author)
  23. Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Yokosuka O, Sarin SK, Omata M. APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Hepatol Int. 2018 Dec 11. doi: 10.1007/s12072-018-9915-5.
  24. Kang XZ, Guo XR, Chen BB, Zhang TY, Yuan Q, Chen PJ, Zhang J, Xia NS. The unique antibody suppresses HBV viremia and reduces hepatocarcinogenesis in HBV-transgenic mice. Hum Vaccin Immunother. 2018 Jul 3;14(7):1779-1781. Epub 2018 Apr 12.
  25. Kao JH, Yu ML, Chen CY, Peng CY, Chen MY, Tang H, Chen Q, Wu JJ. Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study. J Gastroenterol Hepatol. 2018 Jan 18. doi: 10.1111/jgh.14096.
  26. Kao JH. Hepatitis B: From control to cure. J Formos Med Assoc. 2018 Oct;117 (10): 868- 870.
  27. Kumar Jayant, Mikael H. Sodergren, Isabella Reccia, Tomokazu Kusano, Dimitris Zacharoulis, Duncan Spalding, Madhava Pai, Long R. Jiao, Kai Wen Huang*. A Systematic Review and Meta-Analysis Comparing Liver Resection with the Rf-Based Device HabibTM-4X with the Clamp-Crush Technique. Cancers. 2018. November;10(11):428.
  28. Kuo YC, Shih SC, Yu LY, Wu MS, Su TH, Liu CJ, Hu KC. Age and gender may be the key points in hyperglycemic patients with Helicobacter pylori infection combined colorectal adenoma. Helicobactor 2018 Apr;23(2):e12473
  29. Li CL, Li CY, Lin YY, Ho MC, Chen DS, Yeh SH, Chen PJ. Androgen Receptor Enhances Hepatic TERT Transcription after Hepatitis B Virus Integration or Point Mutation in Promoter Region. Hepatology. 2018 Aug 2. [Epub ahead of print]
  30. Liao FM, Chang MH, Ho MC, Chen HL, Ni YH, Hsu HY, Wu JF. Resistance index of hepatic artery can predict anastomotic biliary complications after liver transplantation in children. J Formos Med Assoc. 2018 Apr 16. pii: S0929-6646(18)30004-4. [Epub ahead of print]
  31. Liao SH, Su TH, Jeng YM, Liang PC, Chen DS, Chen CH, Kao JH. Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma. Hepatology. 2018 Jul 16. doi: 10.1002/hep.30162.
  32. Lin CC, Ni YH, Lin LH, Lau BH, Chao HC, Lee HC. Effectiveness of the IMFeD tool for the Identification and Management of Feeding Difficulties in Taiwanese children. Pediatr Neonatol 2018; 59(5):507-14.
  33. Lin CL, Kao JH. Prevention of mother-to-child transmission: the key of hepatitis B virus elimination. Hepatol Int. 2018 Mar;12(2):94-96.
  34. Lin CL, Kao JH. Review article: the prevention of hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2018 Jul;48(1):5-14.
  35. Lin HH, Tseng TC, Kao JH. Large and middle hepatitis B surface antigen: the lower the better? Gut. 2018 Mar 7. pii: gutjnl-2018-316030. [Epub ahead of print]
  36. Lin PH, Wong WI, Wang YL, Hsieh MP, Lu CW, Liang CY, Jui SH, Wu FY, Chen PJ, Yang HC. Vaccine-induced antigen-specific regulatory T cells attenuate the antiviral immunity against acute influenza virus infection. Mucosal Immunol. 2018 Jul;11(4):1239-1253.
  37. Lin PH, Wong WI, Wang YL, Hsieh MP, Lu CW, Liang CY, Jui SH, Wu FY, Chen PJ, Yang HC. Vaccine-induced antigen-specific regulatory T cells attenuate the antiviral immunity against acute influenza virus infection. Mucosal Immunol. 2018 Jul;11(4):1239-1253. Epub 2018 Feb 21.
  38. Lin YC, Chang PF, Chang MH, Ni YH. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children. Liver Int 2018; 38(7):1300-7.
  39. Lin YC, Chang PF, Chang MH, Ni YH. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children. Liver Int. 2018 Jul;38(7):1300-1307.
  40. Liu CH, Chen YS, Wang SS, Liu CJ, Su TH, Yang HC, Hong CM, Chen PJ, Chen DS, Kao JH. Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection. Clin Infect Dis. 2018 Jan 6;66(2):289-292. 
  41. Liu CH, Huang YJ, Yang SS, Chang CH, Yang SS, Sun HY, Liu CJ, Liu WC, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Hung CC, Kao JH. Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. Sci Rep. 2018 Sep 12;8(1):13699.
  42. Liu CH, Liu CJ, Hong CM, Su TH, Yang HC, Chen KM, Huang YP, Yeh YM, Tien HL, Liu YC, Kao JH, Chen DS, Chen PJ. A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018 Jan;33(1):291-297.
  43. Liu CH, Liu CJ, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Kao JH. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. J Gastroenterol Hepatol. 2018 Mar;33(3):710-717.
  44. Liu CH, Sun HY, Liu CJ, Sheng WH, Hsieh SM, Lo YC, Liu WC, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Hung CC, Kao JH. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. Aliment Pharmacol Ther. 2018 Jun;47(12):1690-1698. Epub 2018 Apr 17.
  45. Liu CH, Yu ML, Peng CY, Hsieh TY, Huang YH, Su WW, Cheng PN, Lin CL, Lo CC, Chen CY, Chen JJ, Ma Q, Brooks-Rooney C, Kao JH. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. Aliment Pharmacol Ther. 2018 Dec;48(11-12):1290-1300
  46. Liu CJ, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, Chang TT, Massetto B, Yang JC, Yun C, Knox SJ, Osinusi A, Camus G, Jiang D, Brainard DM, McHutchison JG, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology 2018 Mar;154(4):989-997.
  47. Liu CJ, Tseng TC, Yang WT, Su TH, Yang HC, Liu CH, Chen PJ, Chen DS, Kao JH. Profile and Value of FIB-4 in Patients with Dual Chronic Hepatitis C and B. J Gastroenterol Hepatol 2018 Aug 27. doi: 10.1111/jgh.14455. [Epub ahead of print] (co-corresponding author)
  48. Liu YT, Tseng TC, Soong RS, Peng CY, Cheng YH, Huang SF, Chuang TH, Kao JH, Huang LR. A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment. Journal for ImmunoTherapy of Cancer. 2018 Dec 7;6(1):144., *shared first author.
  49. Nien HC, Sheu JC, Chi YC, Chen CL, Kao JH, Yang WS. One-year weight management lowers lipopolysaccharide-binding protein and its implication in metainflammation and liver fibrosis. PLoS One. 2018 Nov 20;13(11):e0207882.
  50. Papatheodoridis GV, Manolakopoulos S, Su TH, Siakavellas S, Liu CJ, Kourikou A, Yang HC, Kao JH. Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B. Hepatology Aug 31. doi: 10.1002/hep.29497
  51. Po-Li Wei, Long-Teng Lee, Li-Ming Tseng, Kai-Wen Huang, Validation of Assaying Carcinoembryonic Antigen in Human Serum by Using Immunomagnetic Reduction. Scientific Reports. 2018. July;8:10002.
  52. Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 Apr 19. doi: 10.1002/hep.30046.
  53. Reebye V, Huang KW, Lin V, Jarvis S, Cutilas P, Dorman S, Ciriello S, Andrikakou P, Voutila J, Saetrom P, Mintz PJ, Reccia I, Rossi JJ, Huber H, Habib R, Kostomitsopoulos N, Blakey DC, Habib NA. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. Oncogene. 2018 Jun;37(24):3216-3228. doi: 10.1038/s41388-018-0126-2. Epub 2018 Mar 7.
  54. Rivino L, Le Bert N, Gill US, Kunasegaran K, Cheng Y, Tan DZ, Becht E, Hansi NK, Foster GR, Su TH, Tseng TC, Lim SG, Kao JH, Newell EW, Kennedy PT, Bertoletti A. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. J Clin Invest. 2018 Feb 1;128(2):668-681.
  55. Su TH, Liao CH, Liu CH, Huang KW, Tseng TC, Yang HC, Liu CJ ,Chen PJ ,Chen DS , Kao JH. Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. Radiology 2018 JUL;288(1): 293-299
  56. Su TH, Liu CJ, Tseng TC, Chou SW, Liu CH, Yang HC, Wu SJ, Chen PJ, Chen DS, Chen CL, Kao JH. Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2018 Dec 27. . [Epub ahead of print]
  57. Su TH, Tseng TC, Kao JH. HCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed? Hepatology. 2018 Apr;67(4):1634-1635.
  58. Su TH, Yang HC, Tseng TC, Liou JM, Liu CH, Chen CL, Chen PJ, Chen DS, Liu CJ, Kao JH. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. J Infect Dis.2018 Mar 28;217(8):1193-1201.
  59. Su WJ, Chen SF, Yang CH, Chaung PH, Chang HF, Chang MH*. The Impact of Universal Infant Hepatitis B Immunization on Reducing the Hepatitis B Carrier Rate in Pregnant Women. J Infect Dis (In Press).
  60. Surveillance group; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018 May;117(5):381-403.
  61. Tseng CH, Hsu YC, Chang CY, Tseng TC ,Wu MS, Lin JT, Kao JH. Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B. Journal of The Formosan Medical Association.2018 Oct;117(10):915-921
  62. Tseng TC, Liu CJ, Su TH, Yang WT, Chen CL, Yang HC, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. Aliment Pharmacol Ther. 2018 Jun;47(11):1480-1489. doi: 10.1111/apt.14619. Epub 2018 Mar 30.
  63. Tseng WH, Tseng PH, Wu JF, Hsu YC, Lee TY, Ni YH, Wang HP, Hsiao TY, Hsu WC. Double-blind, placebo-controlled study with alginate suspension for laryngopharyngeal reflux disease. Laryngoscope 2018; 128(10):2252-60.
  64. Wang YH, Chuang YH, Wu CF, Jan MC, Wu WJ, Lin CL, Liu CJ, Yang YC, Chen PJ, Lin SM, Tsai MH, Huang YW, Yu MW. Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase. Hepatology 2018 Nov 1. doi: 10.1002/hep.30339. [Epub ahead of print]
  65. Wang YQ, Wu T, Hu DQ, Weng XX, Wang XJ, Chen PJ, Luo XP, Wang HW, Ning Q. Intracellular hepatitis B virus increases hepatic cholesterol deposition in alcoholic fatty liver via hepatitis B core protein. J Lipid Res. 2018 Jan;59(1):58-68.
  66. Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, Kim SU, Lesmana LA, Lin YC, Liu CJ, Ni YH, Sollano J, Wong SK, Wong GL, Chan HL, Farrell G. The Asia-Pacific Working Party on nonalcoholic fatty liver disease guidelines 2017 Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018 Jan;33(1):70-85.
  67. Wu JF, Lee CS, Lin WH, Jeng YM, Chen HL, Ni YH, Hsu HY, Chang MH. Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy. Hepatology. 2018 Feb 27. [Epub ahead of print]
  68. Wu JF, Song SH, Lee CS, Chen HL, Ni YH, Hsu HY, Wu TC,  Chang MH. Clinical Predictors of Liver Fibrosis in Patients With Chronic Hepatitis B Virus Infection From Children to Adults. J Infect Dis. 2018 ;217:1408-1416. 
  69. Wu JF, Song SH, Lee CS, Chen HL, Ni YH, Hsu HY, Wu TC, Chang MH. Clinical predictors of liver fibrosis in patients with chronic hepatitis B virus infection from children to adults. J Infect Dis. 2018 Apr 11;217(9):1408-1416.
  70. Yang HC, Kao JH. Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus. Gut. 2018 Oct 9. pii: gutjnl-2018-317385.
  71. Yang HC, Tsou HH, Pei SN, Chang CS, Chen JH, Yao M, Lin SJ, Lin J, Yuan Q, Xia N, Liu TW, Chen PJ, Cheng AL, Hsu C; Taiwan Cooperative Oncology Group. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. J Hepatol. 2018 Aug;69(2):286-292.
  72. Yang HC, Tsou HH, Pei SN, Chang CS, Chen JH, Yao M, Lin SJ, Lin J, Yuan Q, Xia N, Liu TW, Chen PJ, Cheng AL, Hsu C; Taiwan Cooperative Oncology Group. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. J Hepatol. 2018 Aug;69(2):286-292. Epub 2018 Mar 16.
  73. Yeo YH, Ho HJ, Yang HI, Tseng TC, Hosaka T, Trinh HN, Kwak MS, Park YM, Fung JYY, Buti M, Rodriguez M, Treeprasertsuk S, Preda CM, Ungtrakul T, Charatcharoenwitthaya P, Li X, Li J, Zhang J, Le MH, Wei B, Zou B, Le A, Jeong D, Chien N, Kam L, Lee CC, Riveiro-Barciela M, Istratescu D, Sriprayoon T, Chong Y, Tanwandee T, Kobayashi M, Suzuki F, Yuen MF, Lee HS, Kao JH, Lok AS, Wu CY, Nguyen MH. Factors Associated with Rates of HBsAg Seroclearance in Adults with Chronic HBV Infection: A systematic review and meta-analysis. Gastroenterology. 2018 Oct 17. pii: S0016-5085(18)35158-8.
  74. Younossi ZM, Stepanova M, Henry L, Han KH, Ahn SH, Lim YS, Chuang WL, Kao JH, Nguyen KV, Lai CL, Chan HL, Wei L. Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. J Viral Hepat. 2018 Dec;25(12):1429-1437.
  75. Yu ML, Hung CH, Huang YH, Peng CY, Lin CY, Cheng PN, Chien RN, Hsu SJ, Liu CH, Huang CF, Su CW, Huang JF, Liu CJ, Kao JH, Chuang WL, Chen PJ, Chen DS. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. J Formos Med Assoc. 2018 Dec 4. pii: S0929-6646(18)30756-3. [Epub ahead of print]
  76. Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL. Hepatitis B virus infection. Nat Rev Dis Primers. 2018 Jun 7;4:18035. doi: 10.1038/nrdp.2018.35. Review.

 

 
 

 新聞亮點

 
 
  

 全球B型肝炎 治癒有望!